Skip to main navigation

Codiak Biosciences

Investor Relations - Top Nav

Our Science
Our Science

Through our proprietary engEx™ Platform, we are harnessing the power of nature’s intercellular communication system to engineer a new class of medicines, exosome therapeutics.
Manufacturing
Pipeline & Programs
Pipeline & Programs

We are utilizing our engEx™ Platform to build a broad pipeline of therapeutic candidates that we believe can have a transformative impact on the treatment of a broad spectrum of diseases, with an initial focus on oncology and neurology.
About Us
About Us

At Codiak, we are working to create a major shift in the development of tomorrow’s medicines through scientific ambition, remarkable ingenuity and determined passion for improving patients’ lives.
Careers
Investors & Media
Investors & Media

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines.

News & Events

News & Events menu

Press Releases
Events

CSS to format presentations

September 2022 Corporate Presentation

September 2022 Corporate Presentation

lnk News

Press Releases

View All

September 12, 2022

Codiak Announces Pricing of $20 Million Public Offering of Common Stock and Warrants

September 12, 2022

Codiak Announces Proposed Public Offering of Common Stock and Warrants

August 30, 2022

Codiak BioSciences Announces Program Reprioritization and Corporate Restructuring

lnk Past Events

Events

View Past Events

September 29, 2022

5th Annual Evercore ISI HealthCONx Conference

Join our team of experts working at the forefront of advancing engineered exosomes. Explore Careers

© 2022 All Rights Reserved.

Footer Links

Contact
Privacy Policy
Terms of Use

LinkedIn Twitter